The future of toxicogenomics holds promise for more precise identification of at-risk populations and the development of targeted therapies. Advances in [CRISPR]() technology and high-throughput sequencing are enabling researchers to better understand the genetic basis of toxin sensitivity. This knowledge can lead to improved risk assessment models and more effective interventions to mitigate the adverse effects of toxic exposures.
